SCHEMBL4686722

SCHEMBL4686722

Cc1ccc(-c2ccoc2C(=O)NC2CCN(CCC3(CC(=O)NCC(=O)O)CCCCC3)CC2)cc1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.36
MCHR1 Q99705 4/20 0.36
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
MEN1 O00255 1/20 0.34
S1PR1 P21453 1/20 0.34
TSHR P16473 1/20 0.33
CARM1 Q86X55 1/20 0.33
PRMT6 Q96LA8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
MAPK14 Q16539 1/20 0.33
CACNA1G O43497 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4687554 0.92 L3MBTL1 (0.38) L3MBTL1MCHR1ALDH1A1LMNAKMT2A
SCHEMBL4688414 0.92 L3MBTL1 (0.37) L3MBTL1MCHR1ALDH1A1LMNAKMT2A
SCHEMBL4686652 0.89 PDE10A (0.38) L3MBTL1ALDH1A1LMNAKMT2AKDM4E
SCHEMBL4690432 0.88 MCHR1 (0.39) L3MBTL1MCHR1ALDH1A1LMNAKMT2A
SCHEMBL4693190 0.87 L3MBTL1 (0.39) L3MBTL1MCHR1ALDH1A1LMNAKMT2A
SCHEMBL4687197 0.87 MCHR1 (0.34) L3MBTL1MCHR1ALDH1A1LMNAKMT2A
SCHEMBL4691078 0.86 TSHR (0.41) L3MBTL1MCHR1ALDH1A1LMNAKMT2A
SCHEMBL4687556 0.85 TSHR (0.43) L3MBTL1ALDH1A1LMNAKMT2AKDM4E
SCHEMBL4688285 0.85 L3MBTL1 (0.36) L3MBTL1MCHR1ALDH1A1KMT2ANPC1
SCHEMBL5107097 0.84 L3MBTL1 (0.36) L3MBTL1MCHR1ALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1443046-B1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME KYORIN SEIYAKU KK (JP) 2008-12-17 EP disclosed
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. 2008-08-14 US disclosed
US-7375115-B2 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-05-20 US disclosed
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 US disclosed
EP-1443046-A1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME Kyorin Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same CYP4F2, CYP1A2, CYP4B1 L3MBTL1 4882/4885MCHR1 1825/4885ALDH1A1 383/4885
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same OPRM1, OPRD1, HRH4 L3MBTL1 3273/4885MCHR1 187/4885ALDH1A1 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.